序号 | 受理号 | 药品名称 | 药品类型 | 申请类型 | 注册分类 | 企业名称 | 承办日期 |
1 | JXSS2500002 | 德莫奇单抗注射液 | 治疗用生物制品 | 进口 | 1 | GlaxoSmithKline Trading Services Limited;Glaxo Operati** UK Limited trading as Glaxo Wellcome Operati**;GlaxoSmithKline (China) Investment Co., Ltd.; | 2025/1/4 |
2 | JXSS2500001 | 德莫奇单抗注射液 | 治疗用生物制品 | 进口 | 1 | GlaxoSmithKline Trading Services Limited;Glaxo Operati** UK Limited trading as Glaxo Wellcome Operati**;GlaxoSmithKline (China) Investment Co., Ltd.; | 2025/1/4 |
3 | JXSL2500003 | VG901注射液 | 治疗用生物制品 | 进口 | 1 | ViGeneron GmbH;WuXi Clinical Development Services(Shanghai) Co., Ltd; | 2025/1/4 |
4 | JTH2500002 | 多替诺雷对照品 | 进口 | 化药 | SHIRATORI PHARMACEUTICAL CO.,LTD.?;FUJI YAKUHIN CO.,LTD.?;卫材(中国)药业有限公司; | 2025/1/4 | |
5 | JXSL2500002 | ABBV-400注射用粉末 | 治疗用生物制品 | 进口 | 1 | AbbVie Inc.;AbbVie Pharmaceutical Trading (Shanghai) Co., Ltd.; | 2025/1/3 |
6 | JXSL2500001 | 注射用Budigalimab | 治疗用生物制品 | 进口 | 1 | AbbVie Inc.;AbbVie Pharmaceutical Trading (Shanghai) Co., Ltd.; | 2025/1/3 |
7 | JXHL2500003 | STX-241片 | 化药 | 进口 | 1 | Pierre Fabre Médicament;Fortrea Pharmaceutical Research and Development (Beijing) Co., Ltd.; | 2025/1/3 |
8 | JXHL2500002 | STX-241片 | 化药 | 进口 | 1 | Pierre Fabre Médicament;Fortrea Pharmaceutical Research and Development (Beijing) Co., Ltd.; | 2025/1/3 |
9 | JXHL2500001 | STX-241片 | 化药 | 进口 | 1 | Pierre Fabre Médicament;Fortrea Pharmaceutical Research and Development (Beijing) Co., Ltd.; | 2025/1/3 |
10 | JXSS2400114 | 德莫奇单抗注射液 | 治疗用生物制品 | 进口 | 1 | GlaxoSmithKline Trading Services Limited;Glaxo Operati** UK Limited trading as Glaxo Wellcome Operati**;GlaxoSmithKline (China) Investment Co., Ltd.; | 2025/1/1 |
11 | JXSS2400113 | 德莫奇单抗注射液 | 治疗用生物制品 | 进口 | 1 | GlaxoSmithKline Trading Services Limited;Glaxo Operati** UK Limited trading as Glaxo Wellcome Operati**;GlaxoSmithKline (China) Investment Co., Ltd.; | 2025/1/1 |
12 | JXHS2400124 | 地非法林注射液 | 化药 | 进口 | 5.1 | Vifor Fresenius Medical Care Renal Pharma Ltd.;Siegfried Hameln GmbH;Zhejiang Medical Technology Development Co., LTD.; | 2025/1/1 |
13 | JXHS2400123 | 马昔腾坦他达拉非片 | 化药 | 进口 | 5.1 | Janssen-Cilag International NVenn Pharmaceutical Services Limited;Johnson & Johnson Pharmaceutical Ltd.; | 2025/1/1 |
14 | JXHS2400122 | 马昔腾坦他达拉非片 | 化药 | 进口 | 5.1 | Janssen-Cilag International NVenn Pharmaceutical Services Limited;Johnson & Johnson Pharmaceutical Ltd.; | 2025/1/1 |
15 | JXHL2400308 | 放射性药物镓[68Ga]oxodotreotide注射液配制用药盒 | 化药 | 进口 | 2.4 | Novartis Pharma AG;China Novartis Institutes for BioMedical Research Co., Ltd.; | 2025/1/1 |
16 | JXHL2400307 | 镥[177Lu]oxodotreotide注射液 | 化药 | 进口 | 2.4 | Novartis Pharma AG;China Novartis Institutes for BioMedical Research Co., Ltd.; | 2025/1/1 |
17 | JXHS2400120 | 硫酸艾沙康唑胶囊 | 化药 | 进口 | 5.1 | Basilea Pharmaceutica Deutschland GmbH;SwissCo Services AGfizer Investment CO.,Ltd.; | 2024/12/31 |
18 | JXSL2400258 | 注射用sotatercept | 治疗用生物制品 | 进口 | 3.1 | Merck Sharp & Dohme LLC;MSD R&D (China) Co., Ltd.; | 2024/12/30 |
19 | JXSL2400257 | 注射用sotatercept | 治疗用生物制品 | 进口 | 3.1 | Merck Sharp & Dohme LLC;MSD R&D (China) Co., Ltd.; | 2024/12/30 |
20 | JXHS2400121 | Rilzabrutinib片 | 化药 | 进口 | 1 | Genzyme Corporation;Sanofi S.r.l.;Sanofi (China) Investment Co., Ltd.; | 2024/12/30 |
欢迎光临 药群论坛 (http://yaoqun.net/) | Powered by Discuz! X3.2 |